A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SWOG 1512
- 16 May 2024 Planned End Date changed from 21 Sep 2024 to 4 Jan 2025.
- 23 Sep 2023 Planned End Date changed from 28 Jun 2024 to 21 Sep 2024.
- 30 Jun 2023 Planned End Date changed from 1 Dec 2028 to 28 Jun 2024.